Major Growth Drivers:

What Factors are Causing Market Expeditious Growth in the Biologics CRO Market?

• Growing biologics pipeline and modality complexity: As drug-developers are re-focusing their efforts on next-gen biologics such as gene therapies and cell therapies specialized biologics platforms
• Cost-containment and outsource strategy: Given the continued rise in R&D costs with increased regulatory burden, many pharma and biotech companies are utilizing CROs in order to minimize in-house investments, rationalize their operations, and outsource non-core capabilities such as preclinical testing, bioanalytical study, and clinical trial support.
• Globalization of trials and compliance with regulation: The expansion of CROs into emerging markets, increased growth of clinical trial
• Technological innovations and digital-trial models: Recent advancements, such as Artificial-Intelligence assisted analytics, decentralized/virtual clinical trials, single-use bioreactors and high-throughput biologics screening platforms, have made CROs nimbler and faster at responding to client questions, thus providing an even greater opportunity for biologics outsourcing.

  Key Drifts:

  What Trends are Surfacing in the Biologics Sector?

  The shift towards decentralized and virtual clinical trials for biologics is allowing for more flexible patient recruiting with site-visits reduced substantially. Further, these clinical trial models tend to produce more data on the complexities of therapeutics. As demand for more biosimilars and alternatives to biologics/drugs are rising, sponsors are increasingly employing outsourcing biosimilars as they consider alternatives for development and regulatory in support of biosimilar offerings. Biologics CROs are increasingly advancing and providing integrated end-to-end services, from to laboratory analytics to clinical trial support, to predicative analytics toward clinical development
  Become a valued research partner with us -

  Significant Challenge:

  High Costs and Regulatory Complexity in Biologics Outsourcing:

  Despite significant opportunity in the biologics contract research organization market, one key challenge is that biologic drug development comes with high costs and significant regulatory burden. The nature of biologics typically requires specialized platforms, sophisticated manufacturing and enhanced analytical capabilities, driving development organizations to invest in infrastructure and talent in order to support the biopharma client. Along with their costs, meeting regulatory requirements for biologics (which may include immunogenicity, cell-therapy safety, gene editing oversight, etc.) creates additional challenges and risks to achieving the intended benefits of outsourcing. Each of these factors leads to the potential for delays and/or increased financial risk for the biopharma sponsor and the CRO.

  Regional Analysis:

  North America held the largest share of the biologics contract research organization market due to its well-established pharmaceutical and biotechnology industries, the availability of significant R&D budgets and a mature regulatory environment. Although many of the world's biopharma sponsors are headquartered in North America, the region's position as a leader is supported by strong clusters of clinical-trial sites across the region.

  North America's concentration of the largest sponsors, its strong and established innovation clusters, regulatory incentives, and high per capita healthcare expenditure on R&D-related work are a powerful combination of factors that laid the groundwork for the region's competitive environment. Biologic therapies are likely to proliferate, and while North America remains the largest contributor to clinical-trial CRO work, the country will remain the largest center for outsourcing.

  In contrast, the Asia-Pacific segment represents the largest growth opportunity for biologics CRO activity. Growth is driven by a number of converging factors occurring across many countries in the region (e.g., China, India, South Korea, etc.): increased pharmaceutical and biotechnology R&D activity; likely increased populations suitable for clinical-trial activity; relatively favorable cost structures; and improved regulatory environments to facilitate establishing and growing biologics development.

  Additionally, many of the global sponsors are shifting some of their preclinical and clinical work to Asia-Pacific CROs to manage costs and plan for scale-up of biologics manufacturing in the region. With domestic demand for their own biologics increasing and an inclination to rely on CROs, the Asia-Pacific region is poised for rapid expansion in the next few years.

  Get the latest insights on life science industry segmentation with our Annual Membership:

  Segmental Insights:

  By Type of Biologic:

  The antibodies segment prevailed in 2024 as the use of monoclonal antibodies in the development of therapeutics is expansive. Monoclonal antibodies have demonstrated efficacy, can be easily scaled-up, and have multiple clinical uses in both cancer and autoimmune therapeutics. This clearly indicates that demand for outsourcing to CROs with biologics capabilities remains robust.

  The cell therapies segment is expected to have the most rapid growth in the forecast period, as pharmaceutical innovators are rapidly advancing regenerative and immune-cell based treatments. As CAR-T and stem-cell therapies become more prevalent, sponsors are seeking out biologics CROs for specialized cell-processing, validation, and regulatory support.

  By Scale of Operation:

  The clinical segment was the largest segment of the biologics contract research organization market in 2024, as late-phase biologic trials require large patient populations, coordination over multiple regions, and complex and often comprehensive regulatory submissions to the authorities. Sponsors of studies with late-phase biologics heavily rely on CROs to carry out or manage trial design, patient recruitment, and analytics of the data to submit to authorities for global studies.

  The preclinical segment is expected to show the fastest growth as greater numbers of biologic drug candidates enter early research stages. Biotech companies are increasingly outsourcing their preclinical activities like in-vitro bioassays, pharmacokinetics testing, and toxicity studies to CROs with consolidated and sophisticated biologics research platforms.

  By Target Therapeutic Area:

  Oncology disorders experienced the largest market share in 2024 supported by extensive pipelines of biologics development for oncology disorders. The fragmentation nature of largely single agent antibody immunotherapy preferentially started more reliance on outsourcing for clinical trials and study analysis to CROs who have specialisation in oncology

  Neurological disorders is predicted to grow with the fastest growth trend with the significant increases in biologics innovation for neurodegenerative and central nervous system diseases. With the increase in research focusing on gene and protein-based therapies for disorders such as Alzheimer's and Parkinson's, more reliance on CROs is expected, to provide clinical and analytical support.

  Browse More Insights of Towards Healthcare:

  The global biologics CDMO market size

  The global biological PCR technology market

  The global biologics safety testing market

  The global subcutaneous biologics market

  The filtration in biologics market

  The global cancer biologics market

  The global retinal biologics market

  The global spine biologics market

  Recent Developments:

  • In March 2025, Syngene International (India) acquired its first biologics-facility in the United States (at Baltimore-Bayview) from Emergent BioSolutions to bolster its large-molecule discovery, development and manufacturing services. This expansion reflects strengthening of CRO/CRDMO capabilities for biologics in global-outsourcing markets.
    

  Biologics Contract Research Organization Market Key Players List:

  • Alcami Corporation
  • Alphora, Inc.
  • Catalent, Inc.
  • Curida Holding AS
  • Fujifilm Diosynth Biotechnologies
  • Lonza Group AG
  • MilliporeSigma
  • Samsung Biologics
  • Tanvex CDMO
  • Thermo Fisher Scientific
  • WuXi Biologics
    

  Segments Covered in the Report

  By Type of Biologic

  • Vaccine
  • Cell therapies
  • Gene therapies antibodies
  • Recombinant proteins
  • Peptides
  • Other

  By Scale of Operation

  • Clinical
  • Preclinical

  By Target Therapeutics Areas

  • Oncological disorders
  • Neurological disorders
  • Cardiovascular disorders
  • Inflammatory disorders
  • Other therapeutic area
    

  By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
  Immediate Delivery Available | Buy This Premium Research @

  Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.

  Access the Dashboard:

  About Us

  Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research
  You can place an order or ask any questions, please feel free to contact us at ...

  Europe Region: +44 778 256 0738

  North America Region: +1 8044 4193 44

  APAC Region: +91 9356 9282 04

  Web:

  Our Trusted Data Partners

  Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
  Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest